We are excited to join the Alliance for mRNA Medicines on commenting the FDA’s draft guidance on “Platform Technology Designation Program for Drug Development”. Driven by our proprietary technology platform and two decades of excellence in science and manufacturing, we are dedicated to developing novel treatments that allow the body to produce its own prophylactic and therapeutic drugs.
WEBINAR ALERT: “FDA’s Platform Technology Draft Guidance: What Does it Mean for mRNA Product Development?” This week, AMM responded to FDA’s draft guidance for the Platform Technology Designation Program, encouraging the agency to provide additional details that will enable the full potential of mRNA as a platform for vaccines and therapeutics. (See our FDA response at https://lnkd.in/evWCRNRN) Please join us for a FREE WEBINAR on Wednesday, September 11 at 12:00 pm ET to hear regulatory experts discuss FDA’s draft guidance and explain how mRNA technology’s agility and flexibility make it well suited to a platform approach. We’ll discuss how use of prior knowledge will propel the future of mRNA-based vaccines and therapeutics to treat cancer, rare diseases, autoimmune disorders and more. Register at: https://lnkd.in/ej2v4gFV